Shares of Novavax Inc. were up 2.4% in premarket trading on Friday after the company said its COVID-19 booster was authorized for adults in Canada who were previously immunized with Novavax's protein-based vaccine. The company's stock is down 85.4% this year, while the S&P 500 has declined 17.2%.
(END) Dow Jones Newswires
November 18, 2022 08:27 ET (13:27 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.